Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 05, 2024 07:00 ET | Source: ZyVersa Therapeutics

ZyVersa Therapeutics Highlights Published Data Demonstrating the Potential of Inflammasome Inhibition to Protect Pancreatic Islet Beta Cells and Attenuate Progression from Obesity to Insulin Resistance and Type 2 Diabetes

Inflammasome-driven inflammation in obesity results in severely damaged pancreatic islets, leading to islet cell loss and metabolic dysfunction.